4.8 Article

CASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG

期刊

NATURE COMMUNICATIONS
卷 11, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41467-020-14684-4

关键词

-

资金

  1. Center for Cancer Research, Intramural Research Program at the National Cancer Institute
  2. NATIONAL CANCER INSTITUTE [ZIASC010366, ZIABC010788, ZIABC010806, ZIABC011722, ZIABC011804, ZIABC011734] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Embryonal rhabdomyosarcoma (ERMS) is a childhood cancer that expresses myogenic master regulatory factor MYOD but fails to differentiate. Here, we show that the zinc finger transcription factor CASZ1 up-regulates MYOD signature genes and induces skeletal muscle differentiation in normal myoblasts and ERMS. The oncogenic activation of the RAS-MEK pathway suppresses CASZ1 expression in ERMS. ChIP-seq, ATAC-seq and RNA-seq experiments reveal that CASZ1 directly up-regulates skeletal muscle genes and represses non-muscle genes through affecting regional epigenetic modifications, chromatin accessibility and super-enhancer establishment. Next generation sequencing of primary RMS tumors identified a single nucleotide variant in the CASZ1 coding region that potentially contributes to ERMS tumorigenesis. Taken together, loss of CASZ1 activity, due to RAS-MEK signaling or genetic alteration, impairs ERMS differentiation, contributing to RMS tumorigenesis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Meeting Abstract Oncology

Effects of epigenetic modifier inhibitors on AML cell sensitivity to differentiation therapy

Kalsi K. Heimdal, Edjay Ralph A. Hernandez, Heidi J. Gill Super

CANCER RESEARCH (2018)

Article Genetics & Heredity

Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies

Andrea M. Gross, Megan Frone, Karen W. Gripp, Bruce D. Gelb, Lisa Schoyer, Lisa Schill, Beth Stronach, Leslie G. Biesecker, Dominic Esposito, Edjay Ralph Hernandez, Eric Legius, Mignon L. Loh, Staci Martin, Deborah K. Morrison, Katherine A. Rauen, Pamela L. Wolters, Dina Zand, Frank McCormick, Sharon A. Savage, Douglas R. Stewart, Brigitte C. Widemann, Marielle E. Yohe

AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2020)

Review Cell Biology

The RASopathies: from pathogenetics to therapeutics

Katie E. Hebron, Edjay Ralph Hernandez, Marielle E. Yohe

Summary: The RASopathies are a group of disorders caused by germline mutations in genes encoding components of the RAS/MAPK pathway. This review discusses the pathogenesis of RASopathy-associated genetic variants and the knowledge gained about RAS/MAPK signaling through studying RASopathies. It also explores cell and animal models of RASopathies, emerging RASopathy genes, and the potential use of targeted agents for treating RASopathies. Lastly, it discusses how drugs targeting RAS/MAPK-driven malignancies could be leveraged for patients with RASopathies.

DISEASE MODELS & MECHANISMS (2022)

Article Oncology

Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma

Joshua T. Kowalczyk, Xiaolin Wan, Edjay R. Hernandez, Ruibai Luo, Gaelyn C. Lyons, Kelli M. Wilson, Devorah C. Gallardo, Kristine A. Isanogle, Christina M. Robinson, Arnulfo Mendoza, Christine M. Heske, Jinqui-Qiu Chen, Xiaoling Luo, Alexander E. Kelly, Simone Difilippantinio, Robert W. Robey, Craig J. Thomas, Dan L. Sackett, Deborah K. Morrison, Paul A. Randazzo, Lisa M. Miller Jenkins, Marielle E. Yohe

Summary: Rigosertib inhibits the growth of rhabdomyosarcomas and neuroblastomas by interfering with mitotic spindle assembly, showing potential therapeutic value. Unlike vinca alkaloids, rigosertib does not induce cell death through inhibition of the RAS pathway in RAS-mutated cells, but a combination with the MEK inhibitor trametinib synergistically inhibits tumor growth in certain cell lines.

MOLECULAR CANCER THERAPEUTICS (2021)

暂无数据